Juvenescence Moves IPO To Second Half Of 2020
The UK biotech Juvenescence is valued at $500 million, and it will use public offering to move 5 life extension technologies into phase 2 trials; the biotech incubator is creating medical therapies to increase human longevity. Recently the company has moved its IPO to the second half of 2020, the postponement from an earlier public …